121 related articles for article (PubMed ID: 38893073)
21. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
24. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
25. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.
Kim SH; Jo MW; Kim HJ; Ahn JH
Health Qual Life Outcomes; 2012 Dec; 10():151. PubMed ID: 23244763
[TBL] [Abstract][Full Text] [Related]
26. Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China.
Zhang A; Li J; Mao Z; Wang Z; Wu J; Luo N; Liu P; Wang P
Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38451345
[TBL] [Abstract][Full Text] [Related]
27. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea.
Kim SH; Kim HJ; Lee SI; Jo MW
Qual Life Res; 2012 Aug; 21(6):1065-73. PubMed ID: 21947656
[TBL] [Abstract][Full Text] [Related]
28. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.
Kim EJ; Ko SK; Kang HY
Qual Life Res; 2012 Sep; 21(7):1193-203. PubMed ID: 22012023
[TBL] [Abstract][Full Text] [Related]
29. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
[TBL] [Abstract][Full Text] [Related]
30. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the EQ-5D-5L, EQ-VAS stand-alone component and Oxford knee score in the Australian knee arthroplasty population utilising minimally important difference, concurrent validity, predictive validity and responsiveness.
Lin DY; Cheok TS; Kaambwa B; Samson AJ; Morrison C; Chan T; Kroon HM; Jaarsma RL
Health Qual Life Outcomes; 2023 May; 21(1):41. PubMed ID: 37165364
[TBL] [Abstract][Full Text] [Related]
32. Responsiveness and minimal clinically important difference of EQ-5D-5L in patients with coronary heart disease after percutaneous coronary intervention: A longitudinal study.
Zheng Y; Dou L; Fu Q; Li S
Front Cardiovasc Med; 2023; 10():1074969. PubMed ID: 36970361
[TBL] [Abstract][Full Text] [Related]
33. Construct Validity of the EuroQoL-5 Dimension and the Health Utilities Index in Head and Neck Cancer.
Noel CW; Keshavarzi S; Forner D; Stephens RF; Watson E; Monteiro E; Hosni A; Hansen A; Goldstein DP; de Almeida JR
Otolaryngol Head Neck Surg; 2022 May; 166(5):877-885. PubMed ID: 34311628
[TBL] [Abstract][Full Text] [Related]
34. Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L.
Young TA; Mukuria C; Rowen D; Brazier JE; Longworth L
Med Decis Making; 2015 Oct; 35(7):912-26. PubMed ID: 25997920
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
[TBL] [Abstract][Full Text] [Related]
36. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
37. Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L.
Izumi S; Hagiwara Y; Matsuyama Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2023 Jan; 21(1):3. PubMed ID: 36650539
[TBL] [Abstract][Full Text] [Related]
38. Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629.
Hughes BGM; Mendoza RG; Basset-Seguin N; Vornicova O; Schachter J; Joshi A; Meyer N; Grange F; Piulats JM; Bauman JR; Chirovsky D; Zhang P; Gumuscu B; Swaby RF; Grob JJ
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1777-1790. PubMed ID: 34558040
[TBL] [Abstract][Full Text] [Related]
39. Anxiety, depression, health-related quality of life, and mortality among colorectal patients: 5-year follow-up.
Orive M; Anton-Ladislao A; Lázaro S; Gonzalez N; Bare M; Fernandez de Larrea N; Redondo M; Bilbao A; Sarasqueta C; Aguirre U; Quintana JM;
Support Care Cancer; 2022 Oct; 30(10):7943-7954. PubMed ID: 35737143
[TBL] [Abstract][Full Text] [Related]
40. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
